NCT01464112: A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma |
|
|
| Completed | 1b | 18 | Europe | JNJ-2641585 / VELCADE / Dexamethasone | Janssen Research & Development, LLC | Multiple Myeloma | 11/13 | 11/13 | | |
NCT00677105: A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma. |
|
|
| Completed | 1 | 92 | Europe | JNJ-26481585 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Pharmaceutica N.V., Belgium | Lymphoma, Neoplasms | 09/11 | 09/11 | | |
NCT00676728: A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome |
|
|
| Terminated | 1 | 10 | US | JNJ-26481585 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Advanced or Refractory Leukemia, Myelodysplastic Syndromes | 09/11 | 09/11 | | |
NCT02728492: Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy |
|
|
| Completed | 1 | 51 | RoW | Quisinostat, JNJ-26481585, Paclitaxel, Carboplatin, Gemcitabine, Cisplatin | NewVac LLC, Janssen Pharmaceutica N.V., Belgium | Non-small Cell Lung Cancer, Epithelial Ovarian Cancer | 12/15 | 01/16 | | |
